Popular Trials
Virus Therapy
Oncolytic Virus Therapy for Pancreatic Cancer
Recruiting3 awardsPhase 1 & 2
Houston, Texas
This trial is testing a virus that has been modified to attack cancer cells and also stimulate the immune system to help kill cancer cells. The virus will be injected into the tumor and the patient will also receive standard care treatment.
Virus Therapy
Cocaine Vaccine for Cocaine Addiction
Recruiting0 awardsPhase 1
New York, New York
This trial is testing a new anti-cocaine vaccine to see if it is safe and effective in people addicted to cocaine. The vaccine works by causing the body to create immunity to cocaine, which would then prevent the drug's effects on the brain.
Popular Filters
Trials for Cytomegalovirus Patients
Virus Therapy
Viral-Specific T-cell Therapy for Post-Transplant Viral Infections
Recruiting1 awardPhase 2
Memphis, Tennessee
This trial tests if donor T-cells can safely treat CMV & ADV infections post-transplant. The primary objective is to reduce viral load & secondary is to measure safety & long-term response.
Virus Therapy
Virus-Specific T-Cell Therapy for Infections
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial tests special immune cells designed to fight specific viruses in patients with weak immune systems or those who have had transplants. These patients have infections that don't respond to regular treatments. The donor immune cells help attack the viruses in their bodies. This approach has shown promise in enhancing immune responses to viruses like CMV and EBV.
CAR T-cell Therapy
R-MVST Cells for Viral Infections
Recruiting1 awardPhase 1
New York, New York
This trial is testing a cell therapy called R-MVST for safety and feasibility in patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. The cell therapy will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available.
Trials for CMV Patients
Virus Therapy
Viral-Specific T-cell Therapy for Post-Transplant Viral Infections
Recruiting1 awardPhase 2
Memphis, Tennessee
This trial tests if donor T-cells can safely treat CMV & ADV infections post-transplant. The primary objective is to reduce viral load & secondary is to measure safety & long-term response.
Virus Therapy
Virus-Specific T-Cell Therapy for Infections
Recruiting1 awardPhase 1 & 2
Pittsburgh, Pennsylvania
This trial tests special immune cells designed to fight specific viruses in patients with weak immune systems or those who have had transplants. These patients have infections that don't respond to regular treatments. The donor immune cells help attack the viruses in their bodies. This approach has shown promise in enhancing immune responses to viruses like CMV and EBV.
CAR T-cell Therapy
R-MVST Cells for Viral Infections
Recruiting1 awardPhase 1
New York, New York
This trial is testing a cell therapy called R-MVST for safety and feasibility in patients with refractory viral reactivation and/or symptomatic disease caused by Epstein Barr Virus (EBV), cytomegalovirus (CMV), adenovirus (ADV) or BK virus. The cell therapy will be generated on-demand from the closest partially human leukocyte antigen (HLA)-matched (minimum haploidentical) healthy donors or from the original allo-transplant donor if available.
Trials With No Placebo
Virus Therapy
AdAPT-001 for Cancer
Recruiting1 awardPhase 2
San Marcos, California
This trial is testing a new cancer treatment, AdAPT-001, which is an injected virus that kills cancer cells. The purpose is to find the highest dose that is safe and tolerable. If successful, this could be used to treat others with cancer in the future.
Virus Therapy
HLA-matched VSTs for Viral Infections Post Stem Cell Transplant
Recruiting1 awardPhase 1
Houston, Texas
This trial is for patients who have had a stem cell transplant and have developed a viral infection that is not responding to standard therapy. In this trial, the patient will receive white blood cells that have been specially trained to fight the viral infection.
CAR T-cell Therapy
Adoptive Immunotherapy for Viral Infections
Recruiting1 awardPhase 1 & 2
Washington, District of Columbia
This trial is a Phase I-II dose-finding trial to determine the optimal dose of intravenous injection of donor-derived cytotoxic T lymphocytes specific for CMV, EBV, BKV, and Adenovirus.
T-cell Therapy
Donor T Cell Therapy for Adenovirus Infections
Recruiting1 awardPhase 1
Houston, Texas
This trial is testing the side effects of a new treatment for patients with a weakened immune system and adenovirus-related disease. The treatment is made from donated blood cells and is designed to kill viruses that can cause infections.
View More Related Trials
Frequently Asked Questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.